^
    8d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    27d
    Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Nov 2025 --> Nov 2026 | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    plinabulin (BPI 2358) • Neulasta (pegfilgrastim)
    1m
    RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov)
    P2, N=115, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    Avastin (bevacizumab) • sorafenib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dactinomycin • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • dexrazoxane
    1m
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    1m
    Efficacy and Safety of Pegfilgrastim in Patients With Severe Congenital Neutropenia. (PubMed, EJHaem)
    Larger studies are warranted to evaluate its long-term safety and efficacy. This trial is registered at https://irct.behdasht.gov.ir/ in Iranian Registry of Clinical Trials (IRCT) # IRCT20150125020786N3.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • CSF3R (Colony Stimulating Factor 3 Receptor)
    |
    Neulasta (pegfilgrastim)
    2ms
    BREASTIMMU02: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Neulasta (pegfilgrastim)
    2ms
    BREASTIMMU02: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Centre Leon Berard | Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Neulasta (pegfilgrastim)
    2ms
    MIBG for Refractory Neuroblastoma and Pheochromocytoma (clinicaltrials.gov)
    P=N/A, N=15, Completed, Masonic Cancer Center, University of Minnesota | Suspended --> Completed | N=100 --> 15
    Trial completion • Enrollment change
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2)
    |
    Neulasta (pegfilgrastim) • Azedra (iobenguane I 131)
    3ms
    Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, University of Washington
    New P2 trial
    |
    Rituxan (rituximab) • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    3ms
    Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (clinicaltrials.gov)
    P3, N=1174, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    3ms
    RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov)
    P2, N=115, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jul 2025 --> Dec 2025
    Trial primary completion date
    |
    Avastin (bevacizumab) • sorafenib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dactinomycin • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • dexrazoxane
    3ms
    Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Neulasta (pegfilgrastim) • captisol-enabled melphalan